Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 6/20 | 0.59 |
| ▸ | CDK9 | P50750 | 6/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.59 |
| ▸ | INSR | P06213 | 2/20 | 0.59 |
| ▸ | MET | P08581 | 2/20 | 0.59 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.59 |
| ▸ | CDC7 | O00311 | 1/20 | 0.59 |
| ▸ | PLK4 | O00444 | 1/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.59 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.59 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.59 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.59 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.59 |
| ▸ | PAK4 | O96013 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12570609 | 0.88 | ALK (0.67) | CDK7CDK9ALKINSRMET | |
| SCHEMBL29904751 | 0.87 | CDK7 (0.61) | CDK7CDK9ALKINSRMET | |
| SCHEMBL375003 | 0.87 | CDK7 (0.61) | CDK7CDK9ALKINSRMET | |
| SCHEMBL4107109 | 0.87 | ZAP70 (0.50) | CDK7CDK9ALKINSRMET | |
| SCHEMBL25550984 | 0.83 | CDK7 (0.57) | CDK7CDK9ALKINSRMET | |
| SCHEMBL375360 | 0.80 | ZAP70 (0.61) | CDK7CDK9ALKINSRMET | |
| SCHEMBL12893063 | 0.78 | ALK (0.77) | CDK7CDK9ALKINSRMET | |
| SCHEMBL1912092 | 0.78 | ALK (0.61) | CDK7CDK9ALKINSRMET | |
| Benzamide SCHEMBL2061396 | 0.78 | ALK (0.52) | CDK7CDK9ALKINSRMET | |
| SCHEMBL12311717 | 0.78 | ZAP70 (0.70) | CDK7CDK9ALKINSRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | CDK7 167/4885CDK9 117/4885ALK 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.